Sensoril
AssetAlso withania somnifera, Sensoril®
Standardized Withania somnifera extract with adaptogenic and GABAergic modulation effects
- Stage
- Phase 2
- Modality
- Supplement
- Target
- Oxidative stress and ROS signalling
- 1
- Indication
- 6
- Trials
- 1
- Developer
Indications
1Generalized anxiety disorder
Phase 2, Completed, NCT01311180, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials6
- Evidence for its targets3
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.